Prospective Multicentre Evaluation of PCA3 and TMPRSS2-ERG Gene Fusions as Diagnostic and Prognostic Urinary Biomarkers for Prostate Cancer

Roddam, 2005, Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis, Eur Urol, 48, 386, 10.1016/j.eururo.2005.04.015 Barry, 2001, Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer, N Engl J Med, 344, 1373, 10.1056/NEJM200105033441806 Bussemakers, 1999, DD3: a new prostate-specific gene, highly overexpressed in prostate cancer, Cancer Res, 59, 5975 Tomlins, 2005, Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer, Science, 310, 644, 10.1126/science.1117679 Auprich, 2011, Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging, Eur Urol, 59, 96, 10.1016/j.eururo.2010.10.024 de la Taille, 2011, Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions, J Urol, 185, 2119, 10.1016/j.juro.2011.01.075 Nakanishi, 2008, PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance, J Urol, 179, 1804, 10.1016/j.juro.2008.01.013 Ploussard, 2011, Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance, Eur Urol, 59, 422, 10.1016/j.eururo.2010.11.044 Hessels, 2010, Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer, Prostate, 70, 10, 10.1002/pros.21032 van Gils, 2008, Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results, Prostate, 68, 1215, 10.1002/pros.20781 Cornu, 2013, Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer, Prostate, 73, 242, 10.1002/pros.22563 Magi-Galluzzi, 2011, TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients, Prostate, 71, 489, 10.1002/pros.21265 Laxman, 2006, Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer, Neoplasia, 8, 885, 10.1593/neo.06625 Hessels, 2007, Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer, Clin Cancer Res, 13, 5103, 10.1158/1078-0432.CCR-07-0700 Tomlins, 2011, Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA, Sci Transl Med, 3, 94ra72, 10.1126/scitranslmed.3001970 Bossuyt, 2003, The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration, Clin Chem, 49, 7, 10.1373/49.1.7 Haese, 2008, Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy, Eur Urol, 54, 1081, 10.1016/j.eururo.2008.06.071 Demichelis, 2007, TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort, Oncogene, 26, 4596, 10.1038/sj.onc.1210237 FitzGerald, 2008, Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer, BMC Cancer, 8, 230, 10.1186/1471-2407-8-230 Gopalan, 2009, TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy, Cancer Res, 69, 1400, 10.1158/0008-5472.CAN-08-2467 Nam, 2007, Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer, Br J Cancer, 97, 1690, 10.1038/sj.bjc.6604054 Saramaki, 2008, TMPRSS2:ERG fusion identifies a subgr oup of prostate cancers with a favorable prognosis, Clin Cancer Res, 14, 3395, 10.1158/1078-0432.CCR-07-2051 Wang, 2006, Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer, Cancer Res, 66, 8347, 10.1158/0008-5472.CAN-06-1966 Winnes, 2007, Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer, Oncol Rep, 17, 1033 Groskopf, 2006, APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer, Clin Chem, 52, 1089, 10.1373/clinchem.2005.063289 Hessels, 2003, DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer, Eur Urol, 44, 8, 10.1016/S0302-2838(03)00201-X